IDEV Technologies Announces Completion of SUPERB Clinical Trial Enrollment

By Idev Technologies Incorporated, PRNE
Wednesday, June 1, 2011

WEBSTER, Texas, June 2, 2011 -

- IDE Study Examines Performance of SUPERA(R) Stent in Superficial
Femoral Artery (SFA)

IDEV Technologies, Inc. (IDEV) today announced the completion of
enrollment in the SUPERB Trial, an FDA-approved IDE trial evaluating the use
of IDEV's SUPERA(R) stent system for treatment of peripheral artery disease
in the superficial femoral artery (SFA). Enrollment was completed in May,
making SUPERB one of the fastest enrolling SFA trials.

The trial is a prospective, single-arm study of 258 patients at 49 U.S.
sites, led by national co-investigators Kenneth Rosenfield, M.D., of
Massachusetts General Hospital in Boston and Lawrence Garcia, M.D., of
Steward's St. Elizabeth's Medical Center of Boston. The study objective is to
demonstrate safety and effectiveness of the SUPERA stent in treating
obstructive disease in the SFA.

Dr. Rosenfield summarized, "We are excited to complete enrollment in this
important trial, and will now focus our efforts on patient follow-up and
analysis. Given the encouraging data we've seen from Europe for the SUPERA
stent, and given the stent's outstanding mechanical properties, we are
anxious to finalize our results. It has been a pleasure to work with the
great team of researchers, coordinators, and support staff on this trial."

"Endovascular treatment of the SFA in particular has been problematic for
the millions of patients suffering from PAD in the United States," added Dr.
Garcia. "The unique radial strength and flexibility of the SUPERA stent's
design may provide what has been needed to successfully treat this
challenging vessel."

Dennis Donohoe, M.D., is IDEV's Chief Medical Officer and has served as a
key liaison to the clinical site investigators throughout the trial.
"Completing enrollment of more than 250 pivotal patients in less than two
years is a significant achievement and reflects not only the caliber of our
investigator teams but also their confidence in this stent. I congratulate
the team and look forward to our continued collaboration."

"Completing enrollment in the SUPERB trial is a significant milestone,
and reflects IDEV's ongoing commitment to clinical research," remarked IDEV's
President and Chief Executive Officer Christopher M. Owens.

The SUPERA VERITAS Transhepatic Biliary System currently has 510(k)
clearance in the U.S. for the palliative treatment of biliary strictures
produced by malignant neoplasms. The SUPERB trial results will be used to
support IDEV's pre-market approval (PMA) submission for an additional
peripheral vascular indication.

About IDEV Technologies, Incorporated

IDEV Technologies, Incorporated (IDEV) is an innovator and developer of
next generation medical devices for use in interventional radiology, vascular
surgery and cardiology. IDEV's worldwide headquarters is located in Webster,
and its European headquarters is located in Beuningen, The Netherlands.

The SUPERB Trial (Comparison of the SUPERA PERipheral System to a
Performance Goal Derived from Balloon Angioplasty Clinical Trials in the
Superficial Femoral Artery) is an FDA-approved IDE trial to evaluate SUPERA
in treating patients with obstructive superficial femoral artery (SFA)

The SUPERA stent is currently indicated in the United States for the
palliative treatment of biliary strictures produced by malignant neoplasms
and in Europe, Canada and Australia for the treatment of biliary strictures
produced by malignant neoplasms and for peripheral vascular use following
failed percutaneous transluminal angioplasty (PTA).

For more information please visit

    Contact: Donna Lucchesi
             Vice President Global Marketing
             IDEV Technologies, Incorporated


Pharmaceuticals News

Idev Technologies Incorporated News

will not be displayed